<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29070691</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Structure, Immunogenicity, and Protective Mechanism of an Engineered Enterovirus 71-Like Particle Vaccine Mimicking 80S Empty Capsid.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e01330-17</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01330-17</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) is the major causative agent of severe hand, foot, and mouth disease, which affects millions of young children in the Asia-Pacific region annually. In this study, we engineered a novel EV71 virus-like particle (VLP) that lacks VP4 (therefore designated VLP<sub>&#x394;VP4</sub>) and investigated its structure, antigenicity, and vaccine potential. The cryo-electron microscopy (cryo-EM) structure of VLP<sub>&#x394;VP4</sub> was reconstructed to 3.71-&#xc5; resolution. Results from structural and biochemical analyses revealed that VLP<sub>&#x394;VP4</sub> resembles the end product of the viral uncoating process, the 80S empty capsid. VLP<sub>&#x394;VP4</sub> is able to elicit high-titer neutralizing antibodies and to fully protect mice against lethal viral challenge. Mechanistic studies showed that, at the cellular level, the anti-VLP<sub>&#x394;VP4</sub> sera exert neutralization effects at both pre- and postattachment stages by inhibiting both virus attachment and internalization, and at the molecular level, the antisera can block multiple interactions between EV71 and its key receptors. Our study gives a better understanding of EV71 capsid assembly and provides important information for the design and development of new-generation vaccines for EV71, and perhaps for other enteroviruses, as well.<b>IMPORTANCE</b> Enterovirus 71 (EV71) infection may lead to severe hand, foot, and mouth disease, with significant morbidity and mortality. Knowledge regarding EV71 particle assembly remains limited. Here, we report the generation and characterization of a novel EV71 virus-like particle that lacks the VP4 capsid subunit protein. This particle, termed VLP<sub>&#x394;VP4</sub>, structurally mimics the 80S empty capsid, which is the end stage of EV71 uncoating. We further show that VLP<sub>&#x394;VP4</sub> exhibits desirable immunogenicity and protective efficacy in proof-of-concept studies. In addition, the inhibitory mechanisms of the VLP<sub>&#x394;VP4</sub>-induced antibodies are unraveled at both the cellular and molecular levels. Our work provides the first evidence of picornaviral particle assembly in the complete absence of VP4 and identifies VLP<sub>&#x394;VP4</sub> as an improved EV71 vaccine candidate with desirable traits. These findings not only enhance our understanding of particle assembly and uncoating of picornaviruses, but also provide important information for structure-guided vaccine design for EV71 and other enteroviruses.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 American Society for Microbiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Xiaoli</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Unit of Vaccinology and Antiviral Strategies, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ku</LastName><ForeName>Zhiqiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Unit of Vaccinology and Antiviral Strategies, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Center for Protein Science Shanghai, State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Xiaohua</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Unit of Vaccinology and Antiviral Strategies, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jinhuan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Center for Protein Science Shanghai, State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qingwei</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Unit of Vaccinology and Antiviral Strategies, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Unit of Vaccinology and Antiviral Strategies, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unit of Vaccinology and Antiviral Strategies, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Zhenglin</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>National Center for Protein Science Shanghai, State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Science Research Center, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Xia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Unit of Vaccinology and Antiviral Strategies, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cong</LastName><ForeName>Yao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Center for Protein Science Shanghai, State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China cong@sibcb.ac.cn huangzhong@ips.ac.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Science Research Center, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Zhong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Unit of Vaccinology and Antiviral Strategies, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China cong@sibcb.ac.cn huangzhong@ips.ac.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000623164">VP4 protein, Foot-and-mouth disease virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058425">Vaccines, Virus-Like Particle</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015678">Viral Structural Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002213" MajorTopicYN="N">Capsid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="N">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058425" MajorTopicYN="N">Vaccines, Virus-Like Particle</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015678" MajorTopicYN="N">Viral Structural Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053585" MajorTopicYN="N">Virus Attachment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057646" MajorTopicYN="N">Virus Uncoating</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cryo-EM</Keyword><Keyword MajorTopicYN="N">enterovirus 71</Keyword><Keyword MajorTopicYN="N">structure</Keyword><Keyword MajorTopicYN="N">uncoating</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword><Keyword MajorTopicYN="N">virus-like particle</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>6</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29070691</ArticleId><ArticleId IdType="pmc">PMC5730765</ArticleId><ArticleId IdType="doi">10.1128/JVI.01330-17</ArticleId><ArticleId IdType="pii">JVI.01330-17</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. 2010. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10:778&#x2013;790. doi:10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W, Liao Q, Viboud C, Zhang J, Sun J, Wu JT, Chang Z, Liu F, Fang VJ, Zheng Y, Cowling BJ, Varma JK, Farrar JJ, Leung GM, Yu H. 2014. Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect Dis 14:308&#x2013;318. doi:10.1016/S1473-3099(13)70342-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70342-6</ArticleId><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta C, Walter TS, Evans G, Axford D, Owen R, Rowlands DJ, Wang J, Stuart DI, Fry EE, Rao Z. 2012. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 19:424&#x2013;429. doi:10.1038/nsmb.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Perera R, Cardosa J, Kuhn RJ, Rossmann MG. 2012. Crystal structure of human enterovirus 71. Science 336:1274. doi:10.1126/science.1218713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1218713</ArticleId><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Rossmann MG. 2014. The cellular receptor for enterovirus 71. Protein Cell 5:655&#x2013;657. doi:10.1007/s13238-014-0092-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-014-0092-6</ArticleId><ArticleId IdType="pmc">PMC4145082</ArticleId><ArticleId IdType="pubmed">25103897</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CW, Poh CL, Sam IC, Chan YF. 2013. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. J Virol 87:611&#x2013;620. doi:10.1128/JVI.02226-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02226-12</ArticleId><ArticleId IdType="pmc">PMC3536405</ArticleId><ArticleId IdType="pubmed">23097443</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, Koike S. 2009. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 15:798&#x2013;801. doi:10.1038/nm.1992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1992</ArticleId><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. 2009. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med 15:794&#x2013;797. doi:10.1038/nm.1961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1961</ArticleId><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergelson JM, Coyne CB. 2013. Picornavirus entry. Adv Exp Med Biol 790:24&#x2013;41. doi:10.1007/978-1-4614-7651-1_2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4614-7651-1_2</ArticleId><ArticleId IdType="pubmed">23884584</ArticleId></ArticleIdList></Reference><Reference><Citation>Shingler KL, Yoder JL, Carnegie MS, Ashley RE, Makhov AM, Conway JF, Hafenstein S. 2013. The enterovirus 71 A-particle forms a gateway to allow genome release: a cryoEM study of picornavirus uncoating. PLoS Pathog 9:e1003240. doi:10.1371/journal.ppat.1003240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003240</ArticleId><ArticleId IdType="pmc">PMC3605244</ArticleId><ArticleId IdType="pubmed">23555253</ArticleId></ArticleIdList></Reference><Reference><Citation>Korant BD, Lonbergh K, Stasny JT, Noble J. 1972. Naturally occurring and artificially produced components of 3 rhinoviruses. Virology 48:71. doi:10.1016/0042-6822(72)90115-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(72)90115-8</ArticleId><ArticleId IdType="pubmed">4335940</ArticleId></ArticleIdList></Reference><Reference><Citation>Garriga D, Pickl-Herk A, Luque D, Wruss J, Caston JR, Blaas D, Verdaguer N. 2012. Insights into minor group rhinovirus uncoating: the X-ray structure of the HRV2 empty capsid. PLoS Pathog 8:e1002473. doi:10.1371/journal.ppat.1002473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002473</ArticleId><ArticleId IdType="pmc">PMC3252380</ArticleId><ArticleId IdType="pubmed">22241997</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickl-Herk A, Luque D, Vives-Adrian L, Querol-Audi J, Garriga D, Trus BL, Verdaguer N, Blaas D, Caston JR. 2013. Uncoating of common cold virus is preceded by RNA switching as determined by X-ray and cryo-EM analyses of the subviral A-particle. Proc Natl Acad Sci U S A 110:20063&#x2013;20068. doi:10.1073/pnas.1312128110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1312128110</ArticleId><ArticleId IdType="pmc">PMC3864292</ArticleId><ArticleId IdType="pubmed">24277846</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Guo MS, Lin FH, Hsiao KN, Chang KH, Chou AH, Wang YC, Chen YC, Yang CS, Chong PC. 2011. Purification and characterization of enterovirus 71 viral particles produced from Vero cells grown in a serum-free microcarrier bioreactor system. PLoS One 6:e20005. doi:10.1371/journal.pone.0020005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0020005</ArticleId><ArticleId IdType="pmc">PMC3094384</ArticleId><ArticleId IdType="pubmed">21603631</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JX, Mao QY, Liang ZL, Ji H, Zhu FC. 2014. Development of enterovirus 71 vaccines: from the lab bench to phase III clinical trials. Expert Rev Vaccines 13:609&#x2013;618. doi:10.1586/14760584.2014.897617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2014.897617</ArticleId><ArticleId IdType="pubmed">24621093</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Ohka S, Fujii K, Koike S. 2013. Functional comparison of SCARB2 and PSGL1 as receptors for enterovirus 71. J Virol 87:3335&#x2013;3347. doi:10.1128/JVI.02070-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02070-12</ArticleId><ArticleId IdType="pmc">PMC3592140</ArticleId><ArticleId IdType="pubmed">23302872</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Song Z, Qi Y, Feng X, Xu N, Sun Y, Wu X, Yao X, Mao Q, Li X, Dong W, Wan X, Huang N, Shen X, Liang Z, Li W. 2012. Molecular determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B 2. J Biol Chem 287:6406&#x2013;6420. doi:10.1074/jbc.M111.301622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.301622</ArticleId><ArticleId IdType="pmc">PMC3307280</ArticleId><ArticleId IdType="pubmed">22219187</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Huang JH, Lai CW, Sheng HC, Shih SR, Ho MS, Hu YC. 2006. Expression, purification and characterization of enterovirus-71 virus-like particles. World J Gastroenterol 12:921&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066158</ArticleId><ArticleId IdType="pubmed">16521221</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong M, Zhu H, Zhou J, Yang C, Feng J, Huang X, Ji G, Xu H, Zhu P. 2014. Cryo-electron microscopy study of insect cell-expressed enterovirus 71 and coxsackievirus a16 virus-like particles provides a structural basis for vaccine development. J Virol 88:6444&#x2013;6452. doi:10.1128/JVI.00200-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00200-14</ArticleId><ArticleId IdType="pmc">PMC4093858</ArticleId><ArticleId IdType="pubmed">24672036</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Ye X, Huang X, Cai Y, Liu Q, Li Y, Su Z, Huang Z. 2013. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PLoS One 8:e57601. doi:10.1371/journal.pone.0057601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057601</ArticleId><ArticleId IdType="pmc">PMC3579802</ArticleId><ArticleId IdType="pubmed">23451250</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Ku ZQ, Liu QW, Wang XL, Chen T, Ye XH, Li DP, Jin X, Huang Z. 2015. High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice. Vaccine 33:2335&#x2013;2341. doi:10.1016/j.vaccine.2015.03.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.03.034</ArticleId><ArticleId IdType="pubmed">25820068</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu K, He YL, Li HY, Chen R. 2015. Crystal structures of yeast-produced enterovirus 71 and enterovirus 71/coxsackievirus A16 chimeric virus-like particles provide the structural basis for novel vaccine design against hand-foot-and-mouth disease. J Virol 89:6196&#x2013;6208. doi:10.1128/JVI.00422-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00422-15</ArticleId><ArticleId IdType="pmc">PMC4474312</ArticleId><ArticleId IdType="pubmed">25833050</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Yu CI, Hu YC, Tsai TJ, Kuo YC, Chi WK, Lin AN, Chiang BL. 2012. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine 30:1305&#x2013;1312. doi:10.1016/j.vaccine.2011.12.081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.12.081</ArticleId><ArticleId IdType="pubmed">22214888</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HY, Han JF, Qin CF, Chen R. 2013. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 31:3281&#x2013;3287. doi:10.1016/j.vaccine.2013.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.05.019</ArticleId><ArticleId IdType="pubmed">23726823</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Yan K, Feng Y, Huang X, Ku Z, Cai Y, Liu F, Shi J, Huang Z. 2012. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine 30:6642&#x2013;6648. doi:10.1016/j.vaccine.2012.08.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.08.071</ArticleId><ArticleId IdType="pubmed">22959985</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Li HY, Han JF, Deng YQ, Li YX, Zhu SY, He YL, Qin ED, Chen R, Qin CF. 2013. Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against Coxsackievirus A16 in mice. Appl Microbiol Biotechnol 97:10445&#x2013;10452. doi:10.1007/s00253-013-5257-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-013-5257-3</ArticleId><ArticleId IdType="pubmed">24085395</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren JS, Wang XX, Hu ZY, Gao Q, Sun Y, Li XM, Porta C, Walter TS, Gilbert RJ, Zhao YG, Axford D, Williams M, McAuley K, Rowlands DJ, Yin WD, Wang JZ, Stuart DI, Rao ZH, Fry EE. 2013. Picornavirus uncoating intermediate captured in atomic detail. Nat Commun 4:1929. doi:10.1038/ncomms2889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2889</ArticleId><ArticleId IdType="pmc">PMC3709478</ArticleId><ArticleId IdType="pubmed">23728514</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Ye X, Shi J, Wang X, Liu Q, Huang Z. 2015. Single neutralizing monoclonal antibodies targeting the VP1 GH loop of enterovirus 71 inhibit both virus attachment and internalization during viral entry. J Virol 89:12084&#x2013;12095. doi:10.1128/JVI.02189-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02189-15</ArticleId><ArticleId IdType="pmc">PMC4645313</ArticleId><ArticleId IdType="pubmed">26401034</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y, Ku Z, Liu Q, Leng Q, Huang Z. 2014. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses. Vaccine 32:2406&#x2013;2412. doi:10.1016/j.vaccine.2014.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.03.012</ArticleId><ArticleId IdType="pubmed">24657161</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Liu Q, Ye X, Cai Y, Wang X, Shi J, Li D, Jin X, An W, Huang Z. 2014. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. Vaccine 32:4296&#x2013;4303. doi:10.1016/j.vaccine.2014.06.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.06.025</ArticleId><ArticleId IdType="pubmed">24950363</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YF, Yu CK. 2014. Animal models of enterovirus 71 infection: applications and limitations. J Biomed Sci 21:31. doi:10.1186/1423-0127-21-31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1423-0127-21-31</ArticleId><ArticleId IdType="pmc">PMC4013435</ArticleId><ArticleId IdType="pubmed">24742252</ArticleId></ArticleIdList></Reference><Reference><Citation>Marc D, Girard M, Vanderwerf S. 1991. A Gly1 to Ala substitution in poliovirus capsid protein Vp0 blocks its myristoylation and prevents viral assembly. J Gen Virol 72:1151&#x2013;1157. doi:10.1099/0022-1317-72-5-1151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-72-5-1151</ArticleId><ArticleId IdType="pubmed">1851815</ArticleId></ArticleIdList></Reference><Reference><Citation>Moscufo N, Simons J, Chow M. 1991. Myristoylation is important at multiple stages in poliovirus assembly. J Virol 65:2372&#x2013;2380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240589</ArticleId><ArticleId IdType="pubmed">1850017</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrams CC, King AMQ, Belsham GJ. 1995. Assembly of foot-and-mouth-disease virus empty capsids synthesized by a vaccinia virus expression system. J Gen Virol 76:3089&#x2013;3098. doi:10.1099/0022-1317-76-12-3089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-76-12-3089</ArticleId><ArticleId IdType="pubmed">8847514</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin S, Tuthill TJ, Arias A, Killington RA, Rowlands DJ. 2009. Foot-and-mouth disease virus assembly: processing of recombinant capsid precursor by exogenous protease induces self-assembly of pentamers in vitro in a myristoylation-dependent manner. J Virol 83:11275&#x2013;11282. doi:10.1128/JVI.01263-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01263-09</ArticleId><ArticleId IdType="pmc">PMC2772760</ArticleId><ArticleId IdType="pubmed">19710148</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansardi DC, Porter DC, Morrow CD. 1992. Myristylation of poliovirus capsid precursor-p1 is required for assembly of subviral particles. J Virol 66:4556&#x2013;4563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC241268</ArticleId><ArticleId IdType="pubmed">1318418</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang P, Liu Y, Ma HC, Paul AV, Wimmer E. 2014. Picornavirus morphogenesis. Microbiol Mol Biol Rev 78:418&#x2013;437. doi:10.1128/MMBR.00012-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MMBR.00012-14</ArticleId><ArticleId IdType="pmc">PMC4187686</ArticleId><ArticleId IdType="pubmed">25184560</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesar M, Jia XY, Summers DF, Ehrenfeld E. 1993. Analysis of a potential myristoylation site in hepatitis-A virus capsid protein Vp4. Virology 194:616&#x2013;626. doi:10.1006/viro.1993.1301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1993.1301</ArticleId><ArticleId IdType="pubmed">8389076</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogle JM. 2002. Poliovirus cell entry: common structural themes in viral cell entry pathways. Annu Rev Microbiol 56:677&#x2013;702. doi:10.1146/annurev.micro.56.012302.160757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.micro.56.012302.160757</ArticleId><ArticleId IdType="pmc">PMC1500891</ArticleId><ArticleId IdType="pubmed">12142481</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy HC, Bostina M, Filman DJ, Hogle JM. 2010. Catching a virus in the act of RNA release: a novel poliovirus uncoating intermediate characterized by cryo-electron microscopy. J Virol 84:4426&#x2013;4441. doi:10.1128/JVI.02393-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02393-09</ArticleId><ArticleId IdType="pmc">PMC2863768</ArticleId><ArticleId IdType="pubmed">20181687</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonberg-Holm K, Korant BD. 1972. Early interaction of rhinoviruses with host cells. J Virol 9:29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC356259</ArticleId><ArticleId IdType="pubmed">4333543</ArticleId></ArticleIdList></Reference><Reference><Citation>Bostina M, Levy H, Filman DJ, Hogle JM. 2011. Poliovirus RNA is released from the capsid near a twofold symmetry axis. J Virol 85:776&#x2013;783. doi:10.1128/JVI.00531-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00531-10</ArticleId><ArticleId IdType="pmc">PMC3020038</ArticleId><ArticleId IdType="pubmed">20980499</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bouvier GL. 1955. The modification of poliovirus antigens by heat and ultraviolet light. Lancet ii:1013&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pubmed">13272322</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson M, Minor PD, Magrath DI, Qui YH, Spitz M, Schild GC. 1984. Neutralization epitopes on poliovirus type-3 particles: an analysis using monoclonal-antibodies. J Gen Virol 65:197&#x2013;201. doi:10.1099/0022-1317-65-1-197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-65-1-197</ArticleId><ArticleId IdType="pubmed">6198447</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson M, Minor PD. 1990. Differences in conformation of type-3 poliovirus antigenic sites on noninfectious empty particles and infectious virus. J Gen Virol 71:1271&#x2013;1274. doi:10.1099/0022-1317-71-6-1271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-71-6-1271</ArticleId><ArticleId IdType="pubmed">1693661</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasquez C, Denoya CD, Latorre JL, Palma EL. 1979. Structure of foot-and-mouth-disease virus capsid. Virology 97:195&#x2013;200. doi:10.1016/0042-6822(79)90387-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(79)90387-8</ArticleId><ArticleId IdType="pubmed">38568</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao MG, Butchaiah G, Sen AK. 1994. Antibody-Response to 146s particle, 12s protein subunit and isolated vp1 polypeptide of foot-and-mouth-disease virus type Asia-1. Vet Microbiol 39:135&#x2013;143. doi:10.1016/0378-1135(94)90094-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0378-1135(94)90094-9</ArticleId><ArticleId IdType="pubmed">8203119</ArticleId></ArticleIdList></Reference><Reference><Citation>Noad R, Roy P. 2003. Virus-like particles as immunogens. Trends Microbiol 11:438&#x2013;444. doi:10.1016/S0966-842X(03)00208-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0966-842X(03)00208-7</ArticleId><ArticleId IdType="pubmed">13678860</ArticleId></ArticleIdList></Reference><Reference><Citation>Chackerian B. 2007. Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines 6:381&#x2013;390. doi:10.1586/14760584.6.3.381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.6.3.381</ArticleId><ArticleId IdType="pubmed">17542753</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL. 2007. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res 125:61&#x2013;68. doi:10.1016/j.virusres.2006.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.12.005</ArticleId><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye XH, Fan C, Ku ZQ, Zuo T, Kong LL, Zhang C, Shi JP, Liu QW, Chen T, Zhang YY, Jiang W, Zhang LQ, Huang Z, Cong Y. 2016. Structural basis for recognition of human enterovirus 71 by a bivalent broadly neutralizing monoclonal antibody. PLoS Pathog 12:e1005454. doi:10.1371/journal.ppat.1005454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005454</ArticleId><ArticleId IdType="pmc">PMC4777393</ArticleId><ArticleId IdType="pubmed">26938634</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Shi J, Liu Q, Huang Z. 2012. Development of murine monoclonal antibodies with potent neutralization effects on enterovirus 71. J Virol Methods 186:193&#x2013;197. doi:10.1016/j.jviromet.2012.06.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2012.06.025</ArticleId><ArticleId IdType="pubmed">22771741</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X, Ku Z, Liu Q, Wang X, Shi J, Zhang Y, Kong L, Cong Y, Huang Z. 2014. Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms. J Virol 88:72&#x2013;81. doi:10.1128/JVI.01848-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01848-13</ArticleId><ArticleId IdType="pmc">PMC3911748</ArticleId><ArticleId IdType="pubmed">24131712</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim XF, Jia Q, Chow VTK, Kwang J. 2013. Characterization of a novel monoclonal antibody reactive against the N-terminal region of Enterovirus 71 VP1 capsid protein. J Virol Methods 188:76&#x2013;82. doi:10.1016/j.jviromet.2012.11.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2012.11.038</ArticleId><ArticleId IdType="pubmed">23219932</ArticleId></ArticleIdList></Reference><Reference><Citation>Li QH, Yafal AG, Lee YMH, Hogle J, Chow M. 1994. Poliovirus neutralization by antibodies to internal epitopes of Vp4 and Vp1 results from reversible exposure of these sequences at physiological temperature. J Virol 68:3965&#x2013;3970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC236902</ArticleId><ArticleId IdType="pubmed">7514682</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauter P, Lobert PE, Lucas B, Varela-Calvino R, Alm G, Wattre P, Hober D. 2007. Role of the capsid protein VP4 in the plasma-dependent enhancement of the Coxsackievirus B4E2-infection of human peripheral blood cells. Virus Res 125:183&#x2013;190. doi:10.1016/j.virusres.2007.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2007.01.001</ArticleId><ArticleId IdType="pubmed">17291618</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauter P, Chehadeh W, Lobert PE, Lazrek M, Goffard A, Soumillon M, Caloone D, Vantyghem MC, Weill J, Fajardy I, Alm G, Lucas B, Hober D. 2008. A part of the VP4 capsid protein exhibited by coxsackievirus B4 E2 is the target of antibodies contained in plasma from patients with type 1 diabetes. J Med Virol 80:866&#x2013;878. doi:10.1002/jmv.21171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.21171</ArticleId><ArticleId IdType="pubmed">18366069</ArticleId></ArticleIdList></Reference><Reference><Citation>Chehadeh W, Lobert PE, Sauter P, Goffard A, Lucas B, Weill J, Vantyghem MC, Alm G, Pigny P, Hober D. 2005. Viral protein VP4 is a target of human antibodies enhancing coxsackievirus B4- and B3-induced synthesis of alpha interferon. J Virol 79:13882&#x2013;13891. doi:10.1128/JVI.79.22.13882-13891.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.22.13882-13891.2005</ArticleId><ArticleId IdType="pmc">PMC1280186</ArticleId><ArticleId IdType="pubmed">16254324</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Chen IC, Su LY, Huang KJ, Lei HY, Liu CC. 2010. Enterovirus 71 infection of monocytes with antibody-dependent enhancement. Clin Vaccine Immunol 17:1517&#x2013;1523. doi:10.1128/CVI.00108-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00108-10</ArticleId><ArticleId IdType="pmc">PMC2953001</ArticleId><ArticleId IdType="pubmed">20685937</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen IC, Wang SM, Yu CK, Liu CC. 2013. Subneutralizing antibodies to enterovirus 71 induce antibody-dependent enhancement of infection in newborn mice. Med Microbiol Immunol 202:259&#x2013;265. doi:10.1007/s00430-013-0289-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-013-0289-y</ArticleId><ArticleId IdType="pubmed">23408291</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JF, Cao RY, Deng YQ, Tian X, Jiang T, Qin ED, Qin CF. 2011. Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo. Virol J 8:106. doi:10.1186/1743-422X-8-106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-8-106</ArticleId><ArticleId IdType="pmc">PMC3060144</ArticleId><ArticleId IdType="pubmed">21385398</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao RY, Dong DY, Liu RJ, Han JF, Wang GC, Zhao H, Li XF, Deng YQ, Zhu SY, Wang XY, Lin F, Zhang FJ, Chen W, Qin ED, Qin CF. 2013. Human IgG subclasses against enterovirus type 71: neutralization versus antibody dependent enhancement of infection. PLoS One 8:e64024. doi:10.1371/journal.pone.0064024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0064024</ArticleId><ArticleId IdType="pmc">PMC3659118</ArticleId><ArticleId IdType="pubmed">23700449</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YW, Lin HY, Tsou YL, Chitra E, Hsiao KN, Shao HY, Liu CC, Sia C, Chong P, Chow YH. 2012. Human SCARB2-mediated entry and endocytosis of EV71. PLoS One 7:e30507. doi:10.1371/journal.pone.0030507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0030507</ArticleId><ArticleId IdType="pmc">PMC3260287</ArticleId><ArticleId IdType="pubmed">22272359</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Huang X, Ku Z, Wang T, Liu F, Cai Y, Li D, Leng Q, Huang Z. 2013. Characterization of enterovirus 71 capsids using subunit protein-specific polyclonal antibodies. J Virol Methods 187:127&#x2013;131. doi:10.1016/j.jviromet.2012.09.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2012.09.024</ArticleId><ArticleId IdType="pubmed">23046991</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastronarde DN. 2005. Automated electron microscope tomography using robust prediction of specimen movements. J Struct Biol 152:36&#x2013;51. doi:10.1016/j.jsb.2005.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2005.07.007</ArticleId><ArticleId IdType="pubmed">16182563</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang G, Peng L, Baldwin PR, Mann DS, Jiang W, Rees I, Ludtke SJ. 2007. EMAN2: an extensible image processing suite for electron microscopy. J Struct Biol 157:38&#x2013;46. doi:10.1016/j.jsb.2006.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2006.05.009</ArticleId><ArticleId IdType="pubmed">16859925</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SHW. 2012. RELION: implementation of a Bayesian approach to cryo-EM structure determination. J Struct Biol 180:519&#x2013;530. doi:10.1016/j.jsb.2012.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2012.09.006</ArticleId><ArticleId IdType="pmc">PMC3690530</ArticleId><ArticleId IdType="pubmed">23000701</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang W, Guo F, Liu Z. 2012. A graph theory method for determination of cryo-EM image focuses. J Struct Biol 180:343&#x2013;351. doi:10.1016/j.jsb.2012.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2012.07.005</ArticleId><ArticleId IdType="pmc">PMC3483361</ArticleId><ArticleId IdType="pubmed">22842112</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludtke SJ, Baldwin PR, Chiu W. 1999. EMAN: semiautomated software for high-resolution single-particle reconstructions. J Struct Biol 128:82&#x2013;97. doi:10.1006/jsbi.1999.4174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jsbi.1999.4174</ArticleId><ArticleId IdType="pubmed">10600563</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo F, Jiang W. 2014. Single particle cryo-electron microscopy and 3-D reconstruction of viruses. Methods Mol Biol 1117:401&#x2013;443. doi:10.1007/978-1-62703-776-1_19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-62703-776-1_19</ArticleId><ArticleId IdType="pmc">PMC4020923</ArticleId><ArticleId IdType="pubmed">24357374</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Guo F, Wang F, Li TC, Jiang W. 2016. 2.9 Angstrom resolution Cryo-EM 3D reconstruction of close-packed virus particles. Structure 24:319&#x2013;328. doi:10.1016/j.str.2015.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2015.12.006</ArticleId><ArticleId IdType="pmc">PMC4740195</ArticleId><ArticleId IdType="pubmed">26777413</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. 2004. UCSF Chimera&#x2014;a visualization system for exploratory research and analysis. J Comput Chem 25:1605&#x2013;1612. doi:10.1002/jcc.20084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.20084</ArticleId><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, Schmidt T, Kiefer F, Cassarino TG, Bertoni M, Bordoli L, Schwede T. 2014. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res 42:W252&#x2013;W258. doi:10.1093/nar/gku340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku340</ArticleId><ArticleId IdType="pmc">PMC4086089</ArticleId><ArticleId IdType="pubmed">24782522</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>